David
Santamaría Velilla
Harvard Medical School
Boston, Estados UnidosHarvard Medical School-ko ikertzaileekin lankidetzan egindako argitalpenak (3)
2024
-
Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy
Nature, Vol. 629, Núm. 8013, pp. 919-926
2022
-
Comparative Analysis and Isoform-Specific Therapeutic Vulnerabilities of KRAS Mutations in Non-Small Cell Lung Cancer
Clinical Cancer Research, Vol. 28, Núm. 8, pp. 1640-1650
2016
-
Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma
Nature Medicine, Vol. 22, Núm. 3, pp. 270-277